Hematology and Covid-19
COVID-19 gives as complex medical manifestations, from flu-like signs and symptoms to a couple of organ failure and death. According to the prognosis and remedy protocol for novel coronavirus pneumonia posted through the National Health Commission of China, there are 4 severity tiers of COVID-19 primarily based totally at the medical manifestations: mild, moderate, intense, and essential disease. Severe, in particular essential, instances are normally complex through different organ dysfunctions, such as septic shock, coronary heart failure, and disseminated intravascular coagulation (DIC).
In medical practice, a few thrombotic headaches were mentioned, such as ischaemic limbs, strokes, and venous thromboembolism. Venous thromboembolism is not unusual place in sufferers with intense disease. Although numerous research mentioned that reduced platelet matter and improved D-dimer have been related to intense COVID-19 and excessive mortality, few research have systematically assessed haematological and coagulation parameters amongst sufferers with moderate, intense, and essential COVID-19
- Full blood count and biochemistry findings
- The emerging role of biomarkers procalcitonin, ferritin and C-reactive protein in the prognosis
- Coagulation complications
- Blood and hematopoietic stem cell donation
Related Conference of Hematology and Covid-19
Hematology and Covid-19 Conference Speakers
Recommended Sessions
- Acute and Chronic Lymphocytic Leukemia
- Bone Marrow Transplantation
- Development of Hematopoietic Progenitor and Stem Cells
- Digital imaging in Hematology
- Disorders of Vascular Bleeding
- Epigenetic Mechanisms: Emerging Therapeutic Targets for Blood Disorders
- Genetics, Genomics, and Epigenetics
- Genome Editing and Cellular Therapy
- Hematologic Malignancy
- Hematology and Covid-19
- Hematology-Oncology
- Hemoglobin and Iron Metabolism
- Hemoglobinopathies
- Hemophilia
- Hemostasis and Thrombosis
- Immunology and Immunotherapies
- Multiple Myeloma and Other Plasma Cell Disorders
- Myelodysplastic and Myeloproliferative Disorders
- Pediatric Hematology
- Pharmacology of Chemotherapy
- Radiation Oncology or Cancer Therapy
- Transfusion Medicine
- Types of Blood Disorders
Related Journals
Are you interested in
- Biomarkers in Hematology and Oncology - Hematology Congress 2026 (Germany)
- Blood Disorders: Diagnosis and Treatment - Hematology Congress 2026 (Germany)
- Cancer Genomics & Metabolomics - Hematology Congress 2026 (Germany)
- Case Reports in Hematology - Hematology Congress 2026 (Germany)
- Clinical Haematology - Hematology Congress 2026 (Germany)
- Cord Blood Transplantation - Hematology Congress 2026 (Germany)
- Digital Imaging in Hematology - Hematology Congress 2026 (Germany)
- Haematology and Pharma Industry - Hematology Congress 2026 (Germany)
- Hematologic Cancers - Hematology Congress 2026 (Germany)
- Hematology and Cardio-Oncology - Hematology Congress 2026 (Germany)
- Hematology Nursing - Hematology Congress 2026 (Germany)
- Hematology: Diagnostics and Screening - Hematology Congress 2026 (Germany)
- Hematopoietic Malignancies - Hematology Congress 2026 (Germany)
- Immunohematology - Hematology Congress 2026 (Germany)
- Neuro-Hematology - Hematology Congress 2026 (Germany)
- Organ Specific Cancer - Hematology Congress 2026 (Germany)
- Pediatric Hematology - Hematology Congress 2026 (Germany)
- Stem Cell Therapy - Hematology Congress 2026 (Germany)
- Transfusion Medicines - Hematology Congress 2026 (Germany)
- Vascular Bleeding Disorders - Hematology Congress 2026 (Germany)
